Other Clinical Trial - Resuscitative Thoracotomy Practices

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Status Enrolling by invitation

Clinical Trial Summary

Resuscitative thoracotomies (RT) are an effective life saving measure in appropriate populations [1-8]. Unfortunately, when used outside of these populations the mortality rate is typically more than 90% [1-8]. Western Trauma Association and Eastern Association for the Surgery of Trauma have provided guidelines for which trauma patients are a candidate for RT [1-3].

Clinical Trial Description

EPIC and trauma registry will be queried for demographic information, admission dates, discharge diagnoses, inpatient cognitive function, routine testing (imaging and labs) reports, and surgical histories to determine number of patients who underwent RT, survived the RT, deficits from their cardiac arrest, and if they were COVID-19 positive. A full list of variables to be extracted from the chart review is in Appendix B. Chart review and data collection for these patients should be completed by December of 2024. ;

Study Design

Clinical Trial Details

NCT number	NCT05944003
Study type	Observational
Source	Methodist Health System
Contact
Status	Enrolling by invitation
Phase
Start date	May 18, 2022
Completion date	May 18, 2024

View Details